| 6.02 -0.07 (-1.15%) | 01-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.07 | 1-year : | 9.43 |
| Resists | First : | 6.91 | Second : | 8.07 |
| Pivot price | 6.3  |
|||
| Supports | First : | 5.72 | Second : | 4.98 |
| MAs | MA(5) : | 6.34 |
MA(20) : | 6.04 |
| MA(100) : | 6.88 |
MA(250) : | 7.18 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55.8 |
D(3) : | 69.4 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 11.53 | Low : | 3.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACOG ] has closed above bottom band by 16.5%. Bollinger Bands are 54.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.64 - 6.68 | 6.68 - 6.71 |
| Low: | 5.76 - 5.81 | 5.81 - 5.85 |
| Close: | 5.96 - 6.03 | 6.03 - 6.08 |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Tue, 06 Jan 2026
Hedge funds own 20% of Alpha Cognition Inc. (NASDAQ:ACOG) shares but individual investors control 53% of the company - Yahoo Finance
Thu, 13 Nov 2025
Alpha Cognition (Nasdaq: ACOG) posts 102% order growth as ZUNVEYL prescribers top 500 - Stock Titan
Thu, 02 Oct 2025
Alpha Cognition prices $35M public offering of common shares - MSN
Tue, 30 Sep 2025
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares - Yahoo Finance
Wed, 30 Jul 2025
Individual investors account for 40% of Alpha Cognition Inc.'s (NASDAQ:ACOG) ownership, while hedge funds account for 27% - Yahoo Finance
Wed, 30 Jul 2025
Alpha Cognition: Unheralded Canadian Pharma Set To Launch Alzheimer's Drug - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Financial - Conglomerates
|
|
| Shares Out | 22 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 34 (%) |
| Shares Short | 167 (K) |
| Shares Short P.Month | 79 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.08 |
| Profit Margin | -262.2 % |
| Operating Margin | -187 % |
| Return on Assets (ttm) | -42.3 % |
| Return on Equity (ttm) | -125.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.26 |
| Sales Per Share | 0.34 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -4.37 |
| PEG Ratio | 0 |
| Price to Book value | 2.88 |
| Price to Sales | 17.61 |
| Price to Cash Flow | -8.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|